Supplementary Tables S1-S8. S1: Antibodies used for western blotting, immunoprecipitation and immunofluorescence S2: siRNA libraries and individual siRNAs used in this study S3: Sequences of qPCR primers S4: Z' values in primary siRNA screens S5: Candidate resistance mediators tested in second round screens S6: Validation of screen hits S7: DVL3 expression and clinical parameters in breast and prostate cancer S8:DVL3 IPS on tumor tissue from 22 patients recruited to trials of IGF-1R antibodies